-
DE
GLP-1 (Glucagon-like Peptide-1) is a natural hormone that regulates blood sugar and plays a key role in the treatment of type 2 diabetes and obesity.
Add as Preferred SourceGLP-1 (Glucagon-like Peptide-1) is a natural hormone that regulates blood sugar and plays a key role in the treatment of type 2 diabetes and obesity.
GLP-1 (Glucagon-like Peptide-1) is an incretin hormone produced and released by specialised cells (L-cells) in the small intestine in response to food intake. It belongs to the group of gastrointestinal hormones and plays a central role in regulating blood glucose levels and the feeling of fullness (satiety). In modern medicine, GLP-1 serves as the basis for an important class of drugs used in the treatment of type 2 diabetes and obesity.
GLP-1 exerts its effects through specific GLP-1 receptors found in various organs, including the pancreas, brain, heart, and gastrointestinal tract. Its key actions include:
Because natural GLP-1 is rapidly broken down by the enzyme DPP-4 (dipeptidyl peptidase-4) with a half-life of only 1–2 minutes, it cannot be used therapeutically in its native form. The pharmaceutical industry has therefore developed two drug classes that exploit the GLP-1 signalling pathway:
These agents mimic the action of natural GLP-1 and are protected from enzymatic degradation by DPP-4. Well-known examples include semaglutide, liraglutide, dulaglutide, and exenatide. They are used to treat type 2 diabetes and – at higher doses – for weight management in obesity. Administration is typically via subcutaneous injection; an oral form of semaglutide is also available.
These medications prevent the breakdown of endogenous GLP-1 by the DPP-4 enzyme, thereby extending its duration of action. Examples include sitagliptin and saxagliptin. They have a milder effect compared to GLP-1 receptor agonists but offer a favourable side-effect profile.
In people with type 2 diabetes, GLP-1 secretion after a meal is often reduced – a phenomenon known as the incretin defect. GLP-1-based therapies can compensate for this deficit. These medications effectively lower the HbA1c level (long-term blood glucose marker) with a low risk of hypoglycaemia, since their insulin-stimulating effect is glucose-dependent.
GLP-1 receptor agonists have proven to be an effective therapeutic option for obesity. Through central appetite suppression and delayed gastric emptying, they lead to significant reductions in body weight. Clinical trials with semaglutide (e.g., the STEP trials) demonstrated average body weight reductions of 10–15%.
GLP-1-based therapies are generally well tolerated. Common side effects primarily affect the gastrointestinal tract:
Less common but noteworthy side effects include:
Contraindications exist for certain thyroid conditions (medullary thyroid carcinoma) and a personal or family history of this disease.
GLP-1 research is advancing rapidly. Novel dual and triple receptor agonists (e.g., tirzepatide, which simultaneously activates GLP-1 and GIP receptors) demonstrate even stronger effects on blood glucose and body weight. GLP-1-based approaches are also being investigated for non-alcoholic fatty liver disease (NAFLD), heart failure, and potentially neurodegenerative conditions such as Parkinson's disease.